Cheng Zhengwu, Shao Xinyu, Xu Menglin, Zhou Chunli, Wang Junfeng
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu 241000, People's Republic of China.
Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215006, People's Republic of China.
Cancer Manag Res. 2019 Nov 26;11:9969-9978. doi: 10.2147/CMAR.S226429. eCollection 2019.
Colorectal carcinoma (CRC) is one of the most common malignancies with a dismal 5-year survival rate. The glycolytic enzyme α-enolase () is overexpressed in multiple cancers and is involved in tumor cell proliferation and metastasis. However, its clinical significance, biological role, and underlying molecular mechanisms in CRC are still unclear. The aim of the present study was to investigate the potential role of in the initiation and development of CRC.
The in situ expression of ENO1 in CRC and adjacent normal tissues was examined by immunohistochemistry. The effects of on the in vitro proliferation and migration of CRC cell lines were investigated by MTT, colony formation, and Transwell assays. Finally, the in vivo tumorigenic capacity of ENO1 was assessed in a mouse model.
ENO1 was overexpressed in CRC tissues and significantly correlated with the clinicopathological parameters. Furthermore, Rab1A was also overexpressed in CRC tissues and was positively correlated to that of ENO1. The high expression levels of both ENO1 and Rab1A led to significantly worse prognosis of CRC patients compared to either alone. Furthermore, knockdown of ENO1 significantly inhibited CRC cells proliferation and migration in vitro and reduced xenograft growth in vivo via the concomitant downregulation of Rab1A.
The ENO1/Rab1A signaling axis is involved in CRC progression and is a potential biomarker for the treatment of CRC.
结直肠癌（CRC）是最常见的恶性肿瘤之一，5年生存率较低。糖酵解酶α-烯醇化酶（ENO1）在多种癌症中过表达，参与肿瘤细胞的增殖和转移。然而，其在结直肠癌中的临床意义、生物学作用及潜在分子机制仍不清楚。本研究旨在探讨ENO1在结直肠癌发生发展中的潜在作用。
采用免疫组织化学法检测ENO1在结直肠癌组织及癌旁正常组织中的原位表达。通过MTT、集落形成和Transwell实验研究ENO1对结直肠癌细胞系体外增殖和迁移的影响。最后，在小鼠模型中评估ENO1的体内致瘤能力。
ENO1在结直肠癌组织中过表达，且与临床病理参数显著相关。此外，Rab1A在结直肠癌组织中也过表达，且与ENO1呈正相关。与单独表达相比，ENO1和Rab1A的高表达均导致结直肠癌患者预后明显更差。此外，敲低ENO1可显著抑制结直肠癌细胞的体外增殖和迁移，并通过伴随Rab1A的下调减少体内异种移植瘤的生长。
ENO1/Rab1A信号轴参与结直肠癌进展，是结直肠癌治疗的潜在生物标志物。
